Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine belongs to the NaSSA class and is used to manage depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depression with anxiety features: alleviates both depressive and anxiety symptoms. - Treatment‑resistant depression (adjunct): may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior - Severe hypersensitivity reactions (rash, angioedema) - Hepatic dysfunction - Serotonin syndrome when combined with other serotonergic agents - Unusual bleeding or bruising

Before initiating therapy, clinicians should consider several safety aspects.

- Hepatic function: assess liver status, especially in patients with existing liver disease. - Weight monitoring: track changes due to increased appetite. - Elderly patients: use caution because of heightened risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Bipolar disorder: monitor for possible activation of manic episodes. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase serotonin toxicity. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine levels. - Antihypertensives: additive hypotensive effect. - Anticholinergic drugs: heightened anticholinergic burden. - Carbamazepine: may reduce mirtazapine concentration. - Warfarin: monitor INR for possible alteration.